Three-year efficacy of switching to dolutegravir plus lamivudine: A real-world study.

E PalmierR De MiguelR MontejanoC BuscaR MicánL RamosJ CadiñanosL SerranoJ I BernardinoJosé Ignacio Bernardino SernaE ValenciaJ R ArribasM L MontesJ González-GarcíaL Martín-Carbonero

Published in: HIV medicine (2023)

Our results confirm the real-world, long-term efficacy, tolerability and high genetic barrier of DTG + 3TC in treatment-experienced PWH. Although scarce, mutations causing resistance to nucleosides and integrase can emerge.

Keyphrases

hiv infected patients
open label
randomized controlled trial
clinical trial
antiretroviral therapy
copy number
study protocol
replacement therapy